VALENTINA MARINO
Rome
Profilo professionale
Medical Doctor with 23 years of experience in Medical Affairs, Board-Certified Specialist in Psychiatry, with deep scientific expertise across Rare Cardiology, Rare Diseases, Immunology and CNS. Strong track record in global medical leadership, evidence generation, data strategy, and scientific publications as core drivers of medical strategy and long-term disease leadership in highly competitive and rapidly evolving environments. Recognized for extensive international KOL engagement, cross-functional leadership, and close collaboration countries medical colleagues.
Panoramica
23
23
years of professional experience
Esperienza lavorativa
Sr Global Medical Director, SPC Lead
Pfizer
2023.07 - 2026.03
- Lead the development of high-quality scientific manuscripts, working in close collaboration with international KOLs on data analysis, interpretation, and manuscript generation.
- Lead observational clinical studies, real-world evidence programs, early access program analyses, and post-hoc analyses to address current and future clinical, regulatory, and competitive needs.
- Drive extensive evidence generation and data development activities to drive medical strategy and support lifecycle management for ATTR-CM, in a rapidly changing and increasingly competitive landscape.
- Drive abstract, poster, and oral presentation strategy at major international congresses (ESC, ACC, HFA,), strengthening scientific credibility, visibility, and leadership.
- Maintain and further develop strong, long-standing peer-to-peer relationships with international KOLs, fostering scientific collaboration and co-creation.
- Work in close partnership with internal International and USMA stakeholders, as well as multiple cross-functional partners (Commercial, H&V, HEOR), ensuring full integration of evidence generation into asset strategies.
- Provide matrix management to statisticians, programmers, external agency to develop high quality data and manuscripts promoting innovation, problems solutions and challenging the status quo.
Country Medical Director
Pfizer
Rome
2020.01 - 2023.07
- Directly led all Medical Affairs functions, ensuring operational excellence for customer-facing medical activities, evidence generation, and medical enablement.
- Strategic partner to the Country President/Manager, ensuring alignment with internal and external country strategies.
- Served as the single Medical face of Pfizer toward external stakeholders, including KOLs, industry bodies, regulatory authorities, government institutions, and payers.
- Represented Medical during Business Development discussions in partnership with relevant functions.
- Represented Pfizer Medical through relationships with medical associations, scientific societies, academic medical centers, and industry associations.
- In partnership with Global Medical Affairs, ensured scientific leadership and therapeutic area expertise, promoting a single global medical truth asset by asset.
- Led medical quality and compliance, including inspections, corporate governance, and complaint management.
- Chaired the Country Medical Council (CMC) to ensure compliance, information flow, and resolution of cross-functional issues.
- Represented Medical and partner functions within the Country Management Forum (CMF).
Medical Director – Rare Diseases
Pfizer
Rome
2015.01 - 2020.01
- Responsible for five disease areas: Haemophilia, Endocrinology, Amyloidosis, Transplantation, and Gene Therapy pipeline.
- Extensive external engagement with patient advocacy groups, institutions, regulatory bodies, KOLs, academia, and research centers.
- People management with strong focus on talent development and growth pathways.
- Medical point of reference for Commercial counterparts.
- Accountable for medical governance, compliance, and integrity.
Inflammation & Immunology Lead
Pfizer
Rome
2015.01 - 2015.11
- Responsible for disease area leadership and medical brand plan development and execution for the Inflammation franchise.
- People manager.
- Medical point of reference for external stakeholders (KOLs, HCPs, PAGs, scientific societies).
- Implementation of research projects and publications in collaboration with major universities.
Inflammation & Immunology Medical Manager
Pfizer
Rome
2013.01 - 2014.01
- Member of European strategic medical groups (publications, studies, communication strategy).
- Customer-facing role (advisory boards, investigator-initiated trials, observational studies).
- Development and execution of medical strategic plans across indications.
- Market Access support through real-world data generation and analysis.
- Medical communication strategy for sales and medical field teams.
Medical Advisor – Inflammation & Immunology
Pfizer
Rome
2009.01 - 2013.01
- Contributor to brand plans and medical strategies.
- Management of scientific relationships with KOLs.
- Medical training and support for Sales, MSLs, and Marketing.
- Planning and management of investigator-initiated and observational studies.
- International clinical trial medical monitoring, analysis, and publications.
- Development and review of promotional materials.
- Advisory boards and expert panels implementation and management.
Medical Liaison – Inflammation & Immunology
Pfizer
Rome
2007.01 - 2009.01
- Product and brand medical reference at territory level.
- External expert medical referral.
- Contribution to customer-focused initiatives.
- Support and training for Sales teams.
- Contributor to brand plans and strategies.
- Identification, planning, and management of investigator-initiated studies and surveys.
Medical Advisor – CNS & Pain
Bristol Myers Squibb
2005.01 - 2007.01
Medical Advisor – CNS
Lundbeck Milan
Milan
2003.01 - 2005.01
Istruzione
Board Certification - Psychiatry
University of Rome Tor Vergata
2003-01
Clinical Internship - Psychiatry
University of California, San Diego
2002-01
Doctor of Medicine - undefined
La Sapienza University of Rome
1998-01
LANGUAGES
Italian (Native)
English (Fluent)
Spanish (Basic)
SCIENTIFIC PUBLICATIONS & CONGRESS PRESENTATIONS – FULL LIST
- Peer-Reviewed Journal Publications
- Crespo Leiro MG, Hanna M, Damy T, Delgado D, Ebede B, Marino V, Wang R, Maurer MS, Garcia-Pavia P, Drachman BM. Early access to tafamidis for patients with transthyretin amyloid cardiomyopathy. JACC: Advances. 2025.
- Matucci A, Cammelli D, Cantini F, Goletti D, Marino V, Milano GM, Scarpa R, Tocci G, Maggi E, Vultaggio A. Influence of anti-TNF immunogenicity on safety in rheumatic disease: a narrative review. Expert Opinion on Drug Safety. 2016;15(S1).
- Ceccarelli F, Massafra U, Perricone C, Iodlazzi L, Giacomelli R, Tirri R, Russo R, Pistone G, Ruscitti P, Parisi S, Sainaghi PP, Cacciapaglia F, Zullo A, Marino V, Migliore A, Valesini G. Anti-TNF treatment response in rheumatoid arthritis patients with moderate disease activity: a prospective observational multicentre study (MODERATE). Clinical and Experimental Rheumatology. 2016.
- Minozzi S, Bonovas S, Lytras T, Pecoraro V, González-Lorenzo M, Judina Bastiamipillai A, Gabrielli EM, Lonati AC, Moja L, Cinquini M, Marino V, Matucci A, Milano GM, Tocci G, Scarpa R, Goletti D, Cantini F. Risk of infections using anti-TNF agents in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: a systematic review and meta-analysis. Expert Opinion on Drug Safety. 2016;15(S1).
- Bonovas S, Minozzi S, Lytras T, González-Lorenzo M, Pecoraro V, Colombo S, Polloni I, Moja L, Cinquini M, Marino V, Goletti D, Matucci A, Tocci G, Milano GM, Scarpa R, Cantini F. Risk of malignancies using anti-TNF agents in inflammatory rheumatic diseases: a systematic review and meta-analysis. Expert Opinion on Drug Safety. 2016;15(S1).
- Tocci G, Goletti D, Marino V, Matucci A, Milano GM, Cantini F, Scarpa R. Cardiovascular outcomes and tumour necrosis factor antagonists in chronic inflammatory rheumatic disease: a focus on rheumatoid arthritis. Expert Opinion on Drug Safety. 2016;15(S1).
- Anecchino C, Fanizza C, Marino V, Romero M. Drug outcome survey to evaluate biological treatment in rheumatoid arthritis: an Italian observational study (the DOSE study). Clinical and Experimental Rheumatology.
- Mrowietz U, Chouela EN, Mallbris L, Stefanidis D, Marino V, Pedersen R, Boggs RL. Pruritus and quality of life in moderate-to-severe plaque psoriasis: post hoc explorative analysis from the PRISTINE study. Journal of the European Academy of Dermatology and Venereology. 2015;29(6):1114–20.
- Micali G, Wilsmann-Theis D, Mallbris L, Gallo G, Marino V, Brault Y, Germain JM. Etanercept reduces symptoms and severity of psoriasis after cessation of cyclosporine therapy: results of the SCORE study. Acta Derm Venereol. 2014 Mar 25.
- Ortonne JP, Paul C, Berardesca E, Marino V, Gallo G, Brault Y, Germain JM. 24-week randomized clinical trial investigating the efficacy and safety of two doses of etanercept in nail psoriasis. British Journal of Dermatology. 2012 Sept.
- Rieger E, Wilfley D, Stein R, Marino V, Crow S. A comparison of quality of life in obese individuals with and without binge eating disorder. Int J Eat Disord. 2005 Apr;37(3):234–40.
- Bonaccorso S, Marino V, Biondi M, Grimaldi F, Ippoliti F, Maes M. Depression induced by treatment with interferon-alpha in patients affected by hepatitis C virus. J Affect Disord. 2002 Dec;72(3):237–41.
- Bonaccorso S, Marino V, Puzella A, Pasquini M, Biondi M, Artini M, Almerighi C, Verkerk R, Meltzer H, Maes M. Increased depressive ratings in patients with hepatitis C receiving interferon-alpha-based immunotherapy are related to interferon-alpha-induced changes in the serotonergic system. J Clin Psychopharmacol. 2002 Feb;22(1):86–90.
- Bonaccorso S, Puzella A, Marino V, Pasquini M, Biondi M, Artini M, Almerighi C, Levrero M, Egyed B, Bosmans E, Meltzer HY, Maes M. Immunotherapy with interferon-alpha in patients affected by chronic hepatitis C induces an intercorrelated stimulation of the cytokine network and an increase in depressive and anxiety symptoms. Psychiatry Res. 2001 Dec 15;105(1–2):45–55.
- Maes M, Bonaccorso S, Marino V, Puzella A, Pasquini M, Biondi M, Artini M, Almerighi C, Meltzer H. Treatment with interferon-alpha (IFN alpha) of hepatitis C patients induces lower serum dipeptidyl peptidase IV activity, which is related to IFN alpha-induced depressive and anxiety symptoms and immune activation. Mol Psychiatry. 2001 Jul;6(4):475–80.
- Di Fabio F, Marino V. SSRI pharmacokinetic. In: SSRI in Clinical practice. Loriedo C, Di Fabio F, Vella G. Masson Eds, 2001.
- Manuscripts Submitted / Under Review
- Garcia-Pavia P, Witteles RM, Hanna M, Damy T, Maurer MS, Marino V, Wang R, Crespo Leiro MG, Fontana M. Progression markers in patients with transthyretin amyloid cardiomyopathy treated with tafamidis. Manuscript submitted to JACC.
- Garcia-Pavia P, Hanna M, Marino V, Wang R, Grogan M, Witteles RM. Relative importance of markers of progression in patients with transthyretin amyloid cardiomyopathy receiving tafamidis: a post hoc analysis of Studies 1028 and 1045. Manuscript submitted to C&T under review.
- Major International Congress Presentations
- Crespo Leiro MG, Hanna M, Damy T, Delgado D, Ebede B, Angeli FS, Marino V, Maurer MS, Garcia Pavia P, Drachman BM. Tafamidis treatment for transthyretin amyloid cardiomyopathy: results from an open label, inclusive, early access study (Study 1045, Cohort B). European Society of Cardiology (ESC) Congress, 2024.
- Garcia Pavia P, Marino V, Wang R, Amass L, Maurer MS, et al. Markers of disease progression in patients with transthyretin amyloid cardiomyopathy receiving tafamidis. ESC Congress, 2025.
- Garcia Pavia P, Marino V, Wang R, Amass L, Maurer MS, et al. Clinical progression markers in ATTR CM patients receiving tafamidis: insights from early access and registry datasets. HFA Congress, 2025.
- Marino V, Garcia Pavia P, Maurer MS, Wang R, Amass L, et al. Disease progression and functional improvement in patients with transthyretin amyloid cardiomyopathy treated with tafamidis. American College of Cardiology (ACC) Scientific Sessions, 2025.
- Garcia Pavia P, Hanna M, Marino V, Wang R, Grogan M, Witteles RM. Relative importance of markers of progression in patients with transthyretin amyloid cardiomyopathy receiving tafamidis. Heart Failure Association (HFA) Congress, 2026.
- Garcia Pavia P, Hanna M, Marino V, Wang R, Grogan M, Witteles RM. Relative importance of markers of progression in patients with transthyretin amyloid cardiomyopathy receiving tafamidis: post hoc analysis. Cardiac Society of Australia and New Zealand (CSANZ) Congress, 2026.
- Marino V, Garcia Pavia P, Maurer MS, Wang R, Amass L, et al. Real world disease monitoring and outcomes in patients with transthyretin amyloid cardiomyopathy treated with tafamidis. ACC Scientific Sessions, 2026.
Cronologia
Sr Global Medical Director, SPC Lead
Pfizer
2023.07 - 2026.03
Country Medical Director
Pfizer
2020.01 - 2023.07
Medical Director – Rare Diseases
Pfizer
2015.01 - 2020.01
Inflammation & Immunology Lead
Pfizer
2015.01 - 2015.11
Inflammation & Immunology Medical Manager
Pfizer
2013.01 - 2014.01
Medical Advisor – Inflammation & Immunology
Pfizer
2009.01 - 2013.01
Medical Liaison – Inflammation & Immunology
Pfizer
2007.01 - 2009.01
Medical Advisor – CNS & Pain
Bristol Myers Squibb
2005.01 - 2007.01
Medical Advisor – CNS
Lundbeck Milan
2003.01 - 2005.01
Clinical Internship - Psychiatry
University of California, San Diego
Doctor of Medicine - undefined
La Sapienza University of Rome
Board Certification - Psychiatry
University of Rome Tor Vergata